

00 AUG 14 PM 5:07

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <b>American Pharmaceutical Association</b>			
2. Address <input type="checkbox"/> Check if different than previously reported <b>2215 Constitution Avenue, NW, Washington, DC 20037</b>			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name <b>Mary Singletary</b>	Telephone <b>(202) 429-7572</b>	E-mail (optional) <b>mda@mail.aphanet.com</b>	5. Senate ID# <b>3071-12</b>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID# <b>31620000</b>

**TYPE OF REPORT** 8. Year 2000 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____  <small>income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ <u>134,335.00</u>  <small>Expenses (nearest \$20,000), . . . . .</small></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input checked="" type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature \_\_\_\_\_

Printed Name and Title Mary D. Singletary, Policy & Advocacy, Associate

Registrant Name American Pharmaceutical Assn. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

HR1304: Quality Health Care Coalition Act  
Confidentiality Regulations -- 64 FR 59918-60065, 11/3/99

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate  
Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Susan C. Winkler, RPh		<input type="checkbox"/>
Lisa M. Geiger		<input type="checkbox"/>
Susan K. Bishop		<input checked="" type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature *Mary D. Singletary* Date 8/14/00  
Printed Name and Title Mary D. Singletary, Policy & Advocacy, Associate

Registrant Name American Pharmaceutical Assn Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

- HR4461: FY2001 Agriculture, Rural Develop., FDA-Related Agencies Appropriations Bill
- S 1272/HR 2260: Pain Relief Promotion Act of 1999
- S 941: Conquering Pain Act of 1999
- Regulation of Internet Pharmacies
- FDA Implementation of Dietary Supplement Health and Education Act
- S 2743: Voluntary Error Reduction and Improvement in Patient Safety Act
- S 2549: National Defense Authorization Act for Fiscal Year 2001

17. House(s) of Congress and Federal agencies contacted  Check if None

- U.S. House of Representatives
- U.S. Senate
- Department of Health and Human Services
- Food and Drug Administration
- Drug Enforcement Administration
- White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Susan C. Winckler, RPh		<input type="checkbox"/>
Lisa M. Geiger		<input type="checkbox"/>
Susan K. Bishop		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature Mary D. Singletary Date 8/14/00  
Printed Name and Title Mary D. Singletary, Policy and Advocacy Associate

Registrant Name American Pharmaceutical Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MM4 (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit  
S 841/HR 1495: Access to Prescription Medications in Medicare  
HR 664/S 731: Prescription Drug Fairness Act  
Expanded Coverage for Outpatient Diabetes Self-Management Training Services,  
64 FR 6827, 2/28/99  
Prospective Payment Systems  
HR 4680: Medicare RX 2000 Act  
S 2807: Medicare RX Drug & Modernization Act

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate  
Department of Health and Human Services  
Health Care Financing Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Yes
Susan C. Winckler, RPh		<input type="checkbox"/>
Lisa M. Geiger		<input type="checkbox"/>
Susan K. Bishop		<input checked="" type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature Mary D. Singletary Date 8/14/00  
Printed Name and Title Mary D. Singletary, Policy & Advocacy, Administrative Coordinator

Registrant Name American Pharmaceutical Assn Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues  
S 2758: Medicare Outpatient Drug Act of 2000  
S 2342: Medicare Modernization Act

17. House(s) of Congress and Federal agencies contacted  Check if None  
U.S. House of Representatives  
U.S. Senate  
Department of Health and Human Services  
Health Care Financing Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Susan C. Winckler, RPh		<input type="checkbox"/>
Lisa M. Geiger		<input type="checkbox"/>
Susan K. Bishop		<input checked="" type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature Mary D. Singletary Date 8/14/00  
Printed Name and Title Mary D. Singletary, Policy and Advocacy Associate

Registrant Name American Pharmaceutical Assn Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LER (one per page)

16. Specific lobbying issues

DEA Employment Waiver Notification

Support of Pharmacist Shortage Study S 580, FR Vol. 65, No. 52, pgs 14288-14289

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S House of Representatives

U.S Senate

Drug Enforcement Agency

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Susan C. Winckler, RPh		<input type="checkbox"/>
Lisa M. Geisler		<input type="checkbox"/>
Susan K. Bishop		<input checked="" type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature Mary D. Singletary Date 8/14/00

Printed Name and Title Mary D. Singletary, Policy and Advocacy Associate

Registrant Name American Pharmaceutical Client Name self

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

N/A

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

**ISSUE UPDATE**

24. General lobbying issues previously reported that no longer pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

Signature

*Mary D. Singletary*

Date

8/14/00

Printed Name and Title

Mary D. Singletary, Policy & Advocacy, Administrative Coordinator